摘要
Objective:To evaluate the efficacy of paclitaxel-coated balloon(PCB)in the treatment of extra-long femoropopliteal artery atherosclerotic disease(>30 cm).Materials and methods:Forty-nine patients with extra-long femoropopliteal artery atherosclerotic disease were treated with PCB alone in a single center from July 2016 to May 2018.Primary patency and freedom from clinically driven target lesion revascularization(FF-CDTLR)rates during 12 months were analyzed retrospectively.Results:All patients were followed up for 18.2±7.5 months,and the mean treated lesion length was 34.9±3.7 cm.The primary patency rates were 87.8%(43/49)and 71.4%(35/49)at 6 and 12 months,respectively.FFCDTLR was 91.8%(45/49)and 77.6%(38/49)at 6 and 12 months,respectively.No mortality or amputation occurred in these patients during the follow-up period.Conclusions:PCB has favorable clinical efficacy in patients with extra-long femoropopliteal artery atherosclerotic lesions.
